Business Services Industry

ALCON DEVELOPS NEW FORMULATION OF PATANOL OPHTHALMIC SOLUTION.

AsiaPulse News, January, 2003

$all $us $anr $dru

(Full text of a statement. Contact details below.)

FORT WORTH, Texas, Jan. 23 /PRNewswire-FirstCall-Asianet/ -- Alcon, Inc. (NYSE: ACL) will present the results from two clinical trials involving a new, investigational once-daily formulation of the company's flagship brand PATANOL(R) at the annual meeting of the Western Society of Allergy, Asthma & Immunology (WSAAI) in Hawaii this week.

The first study investigated the product's safety and efficacy up to 24 hours after dosing, while the second evaluated the safety of the drug. This new formulation of PATANOL solution is intended for the once-daily treatment of ocular allergy.

In the first clinical trial, adult subjects were given the study medication once and then...

Premium Content Partnership

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here